Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yukiko Tadokoro is active.

Publication


Featured researches published by Yukiko Tadokoro.


The Journal of Medical Investigation | 2016

Thirty percent of ductal carcinoma in situ of the breast in Japan is extremely low-grade ER(+)/HER2(-) type without comedo necrosis

Miyuki Kanematsu; Masami Morimoto; Masako Takahashi; Junko Honda; Yoshimi Bando; Takuya Moriya; Yukiko Tadokoro; Misako Nakagawa; Hirokazu Takechi; Takahiro Yoshida; Hiroaki Toba; Mitsuteru Yoshida; Aiichiro Kajikawa; Akira Tangoku; Issei Imoto; Mitsunori Sasa

Background Overdiagnosis in mammography (MMG) is a problem. Combination of MMG and ultrasonography for breast cancer screening may increase overdiagnosis. Most cases of overdiagnosis are low-grade ductal carcinoma in situ (LGD), but no reports have focused on them. Materials and methods We immunostained 169 ductal carcinoma in situ (DCIS) cases for ER, PgR, HER2 and Ki67 and classified them into 4 subtypes: ER(+)/HER2(-), ER(+)/HER2(+), ER(-)/HER2(-) and ER(-)/HER2(+). The Ki67 index was used to evaluate the grade of malignancy and examined for correlations with each ER/HER2 subtype and the nuclear grade (NG), with/without comedo necrosis. Results The Ki67 index correlated significantly with NG, both with/without comedo necrosis, and reliably evaluated the grade of malignancy. The index for ER(+)/HER2(-) (n=117, 69.2%) was 7.45±7.10, which was significantly lower than for each of the other types. The index was 5.71±6.94 for ER(+)/HER2(-) without comedo necrosis (n=52, 30.8%), which was significantly lower than with comedo necrosis. This was considered LGD, characterized by absence of microcalcification in MMG and either presence of a solid mass or cystic lesion or absence of hypoechoic areas in ultrasound. Conclusion In Japan, ER(+)/HER2(-) without comedo necrosis accounts for about 30% of DCIS and is LGD. This may be being overdiagnosed. J. Med. Invest. 63: 192-198, August, 2016.


Breast Journal | 2018

T2-hypointense rim of breast mass lesions on magnetic resonance images: Radiologic-pathologic correlation

Kazuaki Nakashima; Takayoshi Uematsu; Takashi Sugino; Kaoru Takahashi; Seiichirou Nishimura; Yukiko Tadokoro; Tomomi Hayashi

We investigated the radiologic‐pathologic correlation of a strong hypointense rim on T2‐weighted images (T2‐hypo‐rim) surrounding breast mass lesions and evaluated its clinical significance. We retrospectively reviewed 3503 consecutive breast magnetic resonance imaging (MRI) examinations. The T2‐hypo‐rim was defined as a border of strong hypointensity compared with the fat signal on fat‐suppressed T2‐weighted images. Detected lesions with T2‐hypo‐rim were classified as a solid or cystic mass with MRI and correlated with histopathologic findings. Sixty‐two masses (2%; 34 solid, 28 cystic) with T2‐hypo‐rim were detected [44 breast cancers, 18 benign lesions, including 15 (24%) papillary tumors]. Patients with cancer were significantly older than those with benign lesions (P = .002). Breast cancers were significantly larger than benign masses (P = .023). In 49 of 62 lesions (24 solid and 16 cystic cancers; three solid and six cystic benign masses), the rims were accurately correlated with the histopathologic findings. All malignant and benign cystic masses exhibited hemosiderin deposits in the cyst walls. However, 22 of 24 solid cancers and no solid benign masses exhibited hemosiderin at the tumor periphery (92% and 0%, respectively, P < .001). In addition, a thick fibrous capsule was present in nine (38%) of 24 solid cancers and none of the solid benign lesions. Strong T2‐hypo‐rims mostly correlated with hemosiderin deposits and/or sometimes fibrous capsules. Although the rims could not distinguish malignant from benign cystic lesions, they indicated malignancy in solid mass lesions on MRI. Additionally, the rims often indicated papillary tumors.


Breast Cancer | 2018

Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery

Kazuaki Nakashima; Takayoshi Uematsu; Kaoru Takahashi; Seiichirou Nishimura; Yukiko Tadokoro; Tomomi Hayashi; Takashi Sugino

BackgroundBreast cancer growth is generally expected to differ between tumor subtypes. We aimed to evaluate tumor doubling time (DT) using ultrasonography and verify whether each tumor subtype has a unique DT.MethodsThis retrospective study included 265 patients with invasive breast cancer who received serial ultrasonography between diagnosis and surgery. Tumor diameters were measured in three directions and DTs were calculated according to an exponential growth model using the volume change during serial ultrasonography. We investigated the relationships between DT, tumor subtype, and histopathological factors.ResultsVolumes did not change in 95 (36%) of 265 tumors and increased in 170 (64%) tumors during serial ultrasonography (mean interval, 56.9 days). The mean volume increases of all tumors and volume-increased tumors were 22.1% and 34.5%, respectively. Triple-negative tumors had greater volume increases (40% vs. 20%, p = 0.001) and shorter DT (124 vs. 185 days, p = 0.027) than estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)– tumors. Volume-increased tumors had higher Ki-67 indices than those of volume-stable tumors in ER+/HER2− (p = 0.002) and ER+/HER2+ tumors (p = 0.011) and higher histological grades in all tumors except triple-negative tumors (p < 0.001). Triple-negative tumors with DTs < 90 days (short-DT) showed higher Ki-67 indices than those with DTs > 90 days (long-DT) (p = 0.008). In ER+/HER2− tumors, histological grades were higher for short-DT than for long-DT tumors (p = 0.022).ConclusionDifferences in tumor DT depending on breast cancer subtype, Ki-67 index, and histological grade were confirmed using serial ultrasonography even during preoperative short interval.


Breast Cancer | 2014

IgG4-related sclerosing disease of the breast successfully treated by steroid therapy

Akiko Ogiya; Kumiko Tanaka; Yukiko Tadokoro; Mariko Kikutani; Takayoshi Uematsu; Hiroya Kashiwagi; Masako Kasami; Kaoru Takahashi


Breast Cancer | 2011

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer

Takayoshi Uematsu; Masako Kasami; Junichiro Watanabe; Kaoru Takahashi; Seiji Yamasaki; Kumiko Tanaka; Yukiko Tadokoro; Akiko Ogiya


Breast Cancer | 2016

Triple assessment of sentinel lymph node metastasis in early breast cancer using preoperative CTLG, intraoperative fluorescence navigation and OSNA.

Mohamed Mokhtar; Yukiko Tadokoro; Misako Nakagawa; Masami Morimoto; Hirokazu Takechi; Kazuya Kondo; Akira Tangoku


Breast Cancer | 2016

Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG)

Misako Nakagawa; Masami Morimoto; Hirokazu Takechi; Yukiko Tadokoro; Akira Tangoku


Breast Cancer | 2012

Clip placement after an 11-gauge vacuum-assisted stereotactic breast biopsy: correlation between breast thickness and clip movement

Takayoshi Uematsu; Masako Kasami; Kaoru Takahashi; Junichiro Watanabe; Seiji Yamasaki; Kumiko Tanaka; Yukiko Tadokoro; Akiko Ogiya


Breast Cancer | 2015

Metastatic breast carcinoma of the abdominal wall muscle: a case report

Akiko Ogiya; Kaoru Takahashi; Mutsumi Sato; Yoshiko Kubo; Noriko Nishikawa; Mariko Kikutani; Yukiko Tadokoro; Kumiko Tanaka; Takayoshi Uematsu; Junichiro Watanabe; Masako Kasami; Seiji Yamasaki


Skin Cancer | 2017

Solitary breast metastasis from malignant melanoma of the scalp : a case report

Kosuke Yoshimi; Tatsuya Shiomi; Hisao Kawahara; Masaki Otsuka; Shusuke Yoshikawa; Yoshio Kiyohara; Tomomi Hayashi; Yukiko Tadokoro; Seiichiro Nishimura; Kaoru Takahashi; Akiko Ishii; Takashi Sugino

Collaboration


Dive into the Yukiko Tadokoro's collaboration.

Top Co-Authors

Avatar

Kaoru Takahashi

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Akiko Ogiya

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Junichiro Watanabe

Japanese Foundation for Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Sugino

Fukushima Medical University

View shared research outputs
Top Co-Authors

Avatar

Junko Honda

University of Tokushima

View shared research outputs
Researchain Logo
Decentralizing Knowledge